CN106176771A - A kind of lamivudine tenofovir Compound Tablet and preparation method thereof - Google Patents
A kind of lamivudine tenofovir Compound Tablet and preparation method thereof Download PDFInfo
- Publication number
- CN106176771A CN106176771A CN201610561406.6A CN201610561406A CN106176771A CN 106176771 A CN106176771 A CN 106176771A CN 201610561406 A CN201610561406 A CN 201610561406A CN 106176771 A CN106176771 A CN 106176771A
- Authority
- CN
- China
- Prior art keywords
- lamivudine
- tenofovir
- microcapsule
- tablet
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
Abstract
The present invention relates to a kind of lamivudine tenofovir Compound Tablet and preparation method thereof.This tablet is made up of principal agent and adjuvant, and principal agent has lamivudine, tenofovir, and adjuvant is diluent, binding agent, disintegrating agent, encapsulating material, Polyethylene Glycol, coating powder, fluidizer etc..Its preparation method is to use spray drying method to prepare lamivudine microcapsule and tenofovir microcapsule respectively, then mixs homogeneously with other pharmaceutically acceptable adjuvants, tabletting, coating.Compared with prior art, lamivudine tenofovir Compound Tablet prepared by the present invention has good stability, and dissolution rate is fast, and technique is the most ripe, is suitable for the advantages such as industrialized production.
Description
Technical field:
The present invention relates to field of medicaments, be specifically related to a kind of lamivudine-tenofovir Compound Tablet and preparation method thereof.
Background technology:
HIV (human immunodeficiency virus) (HIV) is to cause acquired immune deficiency syndrome, namely acquired immune deficiency syndrome (AIDS) (AIDS)
Pathogen.This disease, by destroying immune system, particularly infects cd4 cell and T cell so that host is to opportunistic infection
More sensitive.Inhibition of HIV is often along with AIDS related complex, and this is a kind of with lasting lymphatic disease, fever, body
Heavily alleviate the chronic synthetic disease for characterizing.
Antiretroviral drugs, such as reverse transcriptase inhibitors, hiv protease inhibitor, all it is used for HIV
Treatment.When using HAART method (being commonly called as HAART, HAART), to viral suppression more
Effectively.The compound preparation of lamivudine-tenofovir is applied to the treatment of acquired immune deficiency syndrome (AIDS), and its drug effect is also extensively confirmed,
But the preparation technology of its compound preparation and the quality of the pharmaceutical preparations also have the place that number of values must be improved.
Lamivudine is a kind of nucleoside analog, has suppression viral DNA polymerase and reverse transcriptase activity, to virus
The synthesis of DNA and extend competitive inhibitory action.By being incorporated in viral DNA chain, with the synthesis of blocking virus DNA.
Tenofovir is a kind of nucleotide reverse transcriptase inhibitor, with the side similar with efabirenz
Method suppression reverse transcriptase.Can be combined with natural deoxyribose substrate by direct competitive ground and suppress varial polymerases, and
By inserting, DNA terminates DNA.
Patent document WO2006GB04687 (publication number WO2007/068934) discloses a kind of lamivudine-tenofovir
Compound double-layer tablet, by being pelletized respectively with adjuvant by two kinds of principal agents, obtains after last tabletting.
Patent document WO2008IN00068 (publication number WO2008/096369) discloses a kind of lamivudine-tenofovir
Compound Tablet, is obtained the monolayer tablet of lamivudine-tenofovir Compound Tablet, is then coated and prepares into by dry granulation
Product.
Patent document WO2009IB00339 (publication number WO2009/106954) discloses a kind of stable lamivudine-replace
Nuo Fuwei Compound Tablet, obtains the monolayer tablet of lamivudine-tenofovir Compound Tablet by wet granulation.
Patent document 201310176233.2 discloses a kind of lamivudine-tenofovir compound preparation, and said preparation is permissible
Prevent and treat A type, influenza B and inhibition of HIV.
In existing preparation, due to the contact of two kinds of principal agents, cause the decline of the two stability and have the increase of related substance,
Use double-layer tablet technology to be separated by two kinds of principal agents and cause difficulty in technique to improve, being therefore badly in need of obtaining a kind of preparation method letter
Single, good stability, lamivudine-tenofovir Compound Tablet that dissolution rate is fast.
Summary of the invention:
It is an object of the invention to overcome the deficiencies in the prior art and provide a kind of stable in properties dissolution rate fast rummy husband
Fixed-tenofovir Compound Tablet.
It is a further object to provide the preparation method of a kind of lamivudine-tenofovir Compound Tablet, the method
Simple ripe, the stability that tablet can be effectively improved and the interaction reducing between effective ingredient.
In order to realize the purpose of the present invention, technical scheme is as follows:
The present invention uses microcapsule technology of preparing, not only obtains good stability, and products obtained therefrom content is uniform, and makes
Agent technique is simple, is suitable to commercial production.
The invention provides a kind of lamivudine-tenofovir Compound Tablet, tablet formulation amount by weight percentage, including
Following component: lamivudine or its pharmaceutically acceptable salt 10%-20%, tenofovir or its pharmaceutically acceptable salt
10%-20%, preferred version is 1:1 for the two mass ratio.Diluent 10%-40%, binding agent 3%-10%, disintegrating agent 2%-
10%, encapsulating material 20%-40%, antitackiness agent 2%-10% time prepared by microcapsule, coating powder 1%-5%, fluidizer
0.5%-3%.
Further, described antitackiness agent is Polyethylene Glycol.
Further, lamivudine or its pharmaceutically acceptable salt and tenofovir or its pharmaceutically acceptable salt
Mass ratio is 1:1.
Further, diluent is selected from lactose, and microcrystalline Cellulose, mannitol, one or more of dextrin, binding agent is selected from
Pregelatinized Starch, polyvidone, one or more of hypromellose, disintegrating agent is selected from cross-linking sodium carboxymethyl cellulose, crosslinking
Polyvidone, one or more of carboxymethyl starch sodium, encapsulating material is selected from gelatin, arabic gum, hydroxyethyl cellulose, poly-second
Enol, polyacrylic acid, acrylic resin, one or more of polyvinylpyrrolidone, fluidizer is selected from magnesium stearate, titanium dioxide
Silicon, talcous one or more.
Further, coating powder is Ka Lekang coating powder.
The present invention adds Polyethylene Glycol as antitackiness agent in microcapsule preparation process, and limits its consumption in certain limit,
While playing anti-glutinous effect thus ensureing microencapsulation rate, serve the most unexpectedly and increase preparation at high temperature stability
Effect.
Ka Lekang coating powder of the present invention is a kind of conventional commercial coating material, is mainly used in taste masking, it is to avoid raw material
Bitterness cause patient uncomfortable.
Further, the present invention also provides for a kind of method preparing described lamivudine-tenofovir Compound Tablet, and step is such as
Under: the preparation of (1) lamivudine microcapsule: weigh lamivudine or its pharmaceutically acceptable salt of recipe quantity, encapsulating material,
The mass ratio of the two is 1:2-2:1, is first dissolved in appropriate solvent by encapsulating material, forms solution, this solution material Han microencapsulation
Material 5-30%, adds the Polyethylene Glycol of recipe quantity, adds lamivudine powder or its pharmaceutically acceptable salt, in liquid temperature 5-
Under conditions of 25 DEG C, stirring is to being completely dissolved, and then solution spray drying method is prepared microcapsule, preparation temperature 30-120 DEG C,
Preparation time controls at 30-35 minute, stops when water content≤7% in microcapsule being dried, obtains lamivudine microcapsule, microcapsule
Envelop rate is 95%-99%；(2) preparation of tenofovir microcapsule: weigh the tenofovir of recipe quantity or it is pharmaceutically acceptable
Salt, encapsulating material, the mass ratio of the two is 1:2-2:1, is first dissolved in appropriate solvent by encapsulating material, formed solution,
This solution 5-30% Han encapsulating material, adds the Polyethylene Glycol of recipe quantity, adds tenofovir or it is pharmaceutically acceptable
Salt, under conditions of liquid temperature 5-25 DEG C, solution spray drying method, to being completely dissolved, and then is prepared microcapsule by stirring, preparation
Temperature 30-120 DEG C, preparation time controls at 30-35 minute, stops when water content≤7% in microcapsule being dried, obtains for promise good fortune
Wei microcapsule, the envelop rate of microcapsule is 95%-98%；(3) mixing of adjuvant: by the diluent of recipe quantity, binding agent, disintegrating agent,
Fluidizer puts in fluid bed and mixes, and fully sieves after mixing, and wherein wind speed is set to 25L/min, mixes 10min；(4)
The compacting of label: the adjuvant of the fully mixing obtained in step (3) is added in tablet machine, uses suitable pressure tabletted
Core；(5) coating of tablet: the tablet obtained in step (4) is placed in seed-coating machine, appropriate solvent dissolves coating powder, is coated,
Obtain finished product.
Further, in above-mentioned preparation method, lamivudine powder in step (1), the mass ratio of encapsulating material is preferred
For 1:1；Tenofovir powder in step (2), the mass ratio of encapsulating material is preferably 1:1.
Further, in above-mentioned preparation method, in step (3), screen cloth is preferably 60 mesh sieves.
Further, in above-mentioned preparation method, in step (4), tablet machine pressure is preferably 6.0-7.0MPa.
Further, in above-mentioned preparation method, coating process tablet weightening finish 1%-8% in step (5).
Further, in above-mentioned preparation method, coating process tablet weightening finish 2% in step (5).
The invention have the benefit that 1. technical maturities are simple, by after sifting step is arranged on adjuvant mixing
Be not prepare microcapsule after, thus reduce and sieve number of times, simplify operating process；Although the most not using the bilayer of complex process
Sheet technology of preparing, but cleverly by the method preparing microcapsule in the present invention, it is to avoid contacting with each other of two kinds of principal agents, improves
Tablet stability, further simplify preparation technology simultaneously；3. by the repetition test preparing microcapsule, it was found that one section favourable
In principal agent dissolution, and ensure the preparation time of envelop rate；4. by the repetition test to tableting pressure, it was found that can protect for one section
Card hardness is qualified, can guarantee that again the pressure of dissolution rate；5., additionally, applicant is found surprisingly that, add when preparing microcapsule
Polyethylene Glycol, has the effect increasing tablet at high temperature stability.
Detailed description of the invention:
Comparative example 1
Lamivudine-tenofovir the Compound Tablet prepared by patent document WO2009106954 method:
By above-mentioned formula, by lamivudine, tenofovir disoproxil fumarate, microcrystalline Cellulose, cross-linked carboxymethyl is fine
Dimension element sodium uses wet granulation process to pelletize, and crosses 20 mesh sieves, and granulate is dried.Additional microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose,
Tabletting after magnesium stearate, fully mixing, prepares label.Weigh Opadry coating powder, be dissolved in purified water, to tablet core dosage form bag
Clothing, obtains finished product.
Comparative example 2
According to the preparation method of embodiment 1, difference is to substitute Polyethylene Glycol as antitackiness agent with Talcum.
Comparative example 3
According to the preparation method of embodiment 1, difference is to substitute Polyethylene Glycol as antitackiness agent by magnesium stearate.
Embodiment 1
(1) lamivudine microcapsule is prepared
Weigh 300g acrylic resin, 30g Macrogol 4000, be dissolved in 90% ethanol solution, stir.Weigh
300g lamivudine is dissolved in above-mentioned solution, and stirring, until being completely dissolved, is settled to 5000mL.
Mixed liquor is carried out under conditions of maintaining 40-50 DEG C in inlet temperature 70 DEG C, wind speed 20L/min, outlet temperature
Being spray-dried, the persistent period controls at 30min, it is thus achieved that lamivudine microcapsule.
| Lamivudine | 300g |
| Acrylic resin | 300g |
| Polyethylene Glycol | 30g |
| 90% ethanol | 5000ml |
(2) tenofovir microcapsule is prepared
Weigh 300g acrylic resin, 30g Macrogol 4000, be dissolved in 90% ethanol solution, stir.Weigh
300g tenofovir disoproxil fumarate is dissolved in above-mentioned solution, and stirring, until being completely dissolved, is settled to 5000mL.
Mixed liquor is carried out under conditions of maintaining 40-50 DEG C in inlet temperature 70 DEG C, wind speed 20L/min, outlet temperature
Being spray-dried, the persistent period controls at 30min, it is thus achieved that tenofovir disoproxil fumarate microcapsule.
| Tenofovir disoproxil fumarate | 300g |
| Acrylic resin | 300g |
| Polyethylene Glycol | 30g |
| 90% ethanol | 5000ml |
(3) microcapsule and the mixing of adjuvant
Weigh lamivudine microcapsule 600g, tenofovir microcapsule 600g, add lactose 130g, microcrystalline Cellulose 286g, in advance
Gelling starch 70g, cross-linking sodium carboxymethyl cellulose 75g, magnesium stearate 16g, put in fluid bed, wind speed is set to 25L/min,
Mixing 10min.Mixed granule is crossed 60 mesh sieves.
(4) compacting of tablet
Adding in tablet machine by the granule of the fully mixing obtained in step (3), regulation pressure 7.0MPa is pressed into label.
(5) coating of label
The label obtained in step (4) is placed in seed-coating machine, Ka Lekang coating powder 35g is dissolved in 85% ethanol, fully
Dissolve, and constant volume is to 350ml, is coated, it is thus achieved that finished product.
Embodiment 2
(1) lamivudine microcapsule is prepared
Weigh 300g acrylic resin, 30g Macrogol 4000, be dissolved in 90% ethanol solution, stir.Weigh
200g lamivudine is dissolved in above-mentioned solution, and stirring, until being completely dissolved, is settled to 5000mL.
Mixed liquor is carried out under conditions of maintaining 40-50 DEG C in inlet temperature 70 DEG C, wind speed 20L/min, outlet temperature
Being spray-dried, the persistent period controls at 35min, it is thus achieved that lamivudine microcapsule.
| Lamivudine | 200g |
| Acrylic resin | 300g |
| Polyethylene Glycol | 30g |
| 90% ethanol | 5000ml |
(2) tenofovir microcapsule is prepared
Weigh 300g acrylic resin, 30g Macrogol 4000, be dissolved in 90% ethanol solution, stir.Weigh
300g tenofovir disoproxil fumarate is dissolved in above-mentioned solution, and stirring, until being completely dissolved, is settled to 5000mL.
Mixed liquor is carried out under conditions of maintaining 40-50 DEG C in inlet temperature 70 DEG C, wind speed 20L/min, outlet temperature
Being spray-dried, the persistent period controls at 35min, it is thus achieved that tenofovir disoproxil fumarate microcapsule.
(3) microcapsule and the mixing of adjuvant
Weigh lamivudine microcapsule 500g, tenofovir microcapsule 600g, add lactose 130g, microcrystalline Cellulose 286g, in advance
Gelling starch 70g, cross-linking sodium carboxymethyl cellulose 75g, magnesium stearate 16g, put in fluid bed, wind speed is set to 25L/min,
Mixing 10min.Mixed granule is crossed 60 mesh sieves.
(4) compacting of tablet
Adding in tablet machine by the granule of the fully mixing obtained in step (3), regulation pressure 7.0MPa is pressed into label.
(5) coating of label
The label obtained in step (4) is placed in seed-coating machine, Ka Lekang coating powder 35g is dissolved in 85% ethanol, fully
Dissolve, and constant volume is to 350ml, is coated, it is thus achieved that finished product.
Embodiment 3
(1) lamivudine microcapsule is prepared
Weigh 300g acrylic resin, 30g Macrogol 4000, be dissolved in 90% ethanol solution, stir.Weigh
300g lamivudine is dissolved in above-mentioned solution, and stirring, until being completely dissolved, is settled to 5000mL.
Mixed liquor is carried out under conditions of maintaining 40-50 DEG C in inlet temperature 70 DEG C, wind speed 20L/min, outlet temperature
Being spray-dried, the persistent period controls at 35min, it is thus achieved that lamivudine microcapsule.
| Lamivudine | 300g |
| Acrylic resin | 300g |
| Polyethylene Glycol | 30g |
| 90% ethanol | 5000ml |
(2) tenofovir microcapsule is prepared
Weigh 300g acrylic resin, 30g Macrogol 4000, be dissolved in 90% ethanol solution, stir.Weigh
200g tenofovir disoproxil fumarate is dissolved in above-mentioned solution, and stirring, until being completely dissolved, is settled to 5000mL.
Mixed liquor is carried out under conditions of maintaining 40-50 DEG C in inlet temperature 70 DEG C, wind speed 20L/min, outlet temperature
Being spray-dried, the persistent period controls at 35min, it is thus achieved that tenofovir disoproxil fumarate microcapsule.
| Tenofovir disoproxil fumarate | 200g |
| Acrylic resin | 300g |
| Polyethylene Glycol | 30g |
| 90% ethanol | 5000ml |
(3) microcapsule and the mixing of adjuvant
Weigh lamivudine microcapsule 600g, tenofovir microcapsule 500g, add lactose 130g, microcrystalline Cellulose 286g, in advance
Gelling starch 70g, cross-linking sodium carboxymethyl cellulose 75g, magnesium stearate 16g, put in fluid bed, wind speed is set to 25L/min,
Mixing 10min.Mixed granule is crossed 60 mesh sieves.7MPa
(4) compacting of tablet
Adding in tablet machine by the granule of the fully mixing obtained in step (3), regulation pressure 7.0MPa is pressed into label.
(5) coating of label
The label obtained in step (4) is placed in seed-coating machine, Ka Lekang coating powder 35g is dissolved in 85% ethanol, fully
Dissolve, and constant volume is to 350ml, is coated, it is thus achieved that finished product.
Embodiment 4
Mensuration Dissolution of Tablet:
Measure 0.1mol/L hydrochloric acid solution 900ml respectively and put in each stripping rotor, the actual volume measured and prescribed volume
Deviation should treat that dissolution medium temperature constant, at 37 DEG C ± 0.5 DEG C, takes comparative example 1 respectively within the scope of ± 1%, embodiment 1,
2, during the test sample 6 in 3 puts into stripping rotor, it is respectively sample time 5,10,15,20,30,45 minutes, measures every dissolution
Amount.Experimental result is shown in Table 1, table 2.Dissolution data shows, two kinds of principal agent compositions of embodiment 1,2,3 dissolution when 5 minutes
Already more than 80%, higher than the experimental data of comparative example 1, thus may certify that the spy that in the application, compound preparation dissolution rate is fast
Point.
Table 1: comparative example 1, the dissolution (%) of lamivudine composition in embodiment 1,2,3
Table 2: comparative example 1, the dissolution (%) of tenofovir disoproxil fumarate composition in embodiment 1,2,3
Embodiment 5
The mensuration tablet content uniformity:
Each Example 1,2,3 finished tablet 10, measures lamivudine in principal agent, the relative amount of tenofovir respectively
(labelled amount is 100), as shown in table 3.Understand through calculating, the uniformity of dosage units symbol of two kinds of principal agent compositions in embodiment 1,2,3
Close requirement.
Table 3: lamivudine, the uniformity of dosage units of tenofovir disoproxil fumarate composition in embodiment 1,2,3
Embodiment 6
The investigation of microencapsulation rate.Microencapsulation rate can be calculated by below equation:
Drug loading/(content of dispersion in drug loading+medium in microcapsule) in envelop rate=microcapsule
Embodiment 1,2, the envelop rate of microcapsule such as table 4 in 3, shown in table 5.From data, microencapsulation rate is higher than 95%,
It can be considered that principal agent is well wrapped in capsule material, this provides the foundation for increasing preparation stability.
Table 4: the envelop rate of lamivudine microcapsule in embodiment 1,2,3
| Lamivudine | Envelop rate % |
| Embodiment 1 | 96 |
| Embodiment 2 | 98 |
| Embodiment 3 | 95 |
Table 5: the envelop rate of tenofovir disoproxil fumarate microcapsule in embodiment 1,2,3
| Tenofovir disoproxil fumarate | Envelop rate % |
| Embodiment 1 | 98 |
| Embodiment 2 | 98 |
| Embodiment 3 | 96 |
Embodiment 7
Tablet Acceleration study:
Take comparative example 1, embodiment 1,2,3 finished tablet respectively, carry out tablet accelerated test.
Take test sample three batches, place 6 months under the conditions of temperature 40 DEG C ± 2 DEG C, relative humidity 75% ± 5%, at the 1st
Month, the 2nd month, the 3rd month, separately sampled when the 6th month, result was as shown in table 6,7,8,9.From data, embodiment 1,
2,3 stability in the present context are better than comparative example 1.
Table 6: accelerated test content in January, have related substance and dissolution data
Table 7: accelerated test content in February, have related substance and dissolution data
Table 8: accelerated test content in March, have related substance and dissolution data
Table 9: accelerated test content in June, have related substance and dissolution data
In sum, using the product that the method for preparing tablet thereof of embodiment 1,2,3 obtains, stability is better than conventional method
The product obtained such as wet granulation.
Embodiment 8
Tablet influence factor tests:
Take comparative example 2,3 respectively, the finished tablet (100) of embodiment 1,2,3, carry out hot test, high wet test and
Strong illumination is tested.
Hot test:
Tablet opening is put in incubator, places 10 days at a temperature of 60 DEG C, in sampling in the 5th day and the 10th day, the property of detection tablet
Shape, has related substance and dissolution, and result of the test such as table 10, shown in table 11.From data, under conditions of high temperature (60 DEG C),
The stability comparative example to be significantly better than 2,3 of embodiment 1,2,3.
Table 10: 5 days character of hot test, content, dissolution data
Table 11: 10 days character of hot test, content, dissolution data
High wet test:
Tablet opening is put in incubator, places 10 days under the conditions of relative humidity 90% ± 5% at 25 DEG C, in the 5th day
With sampling in the 10th day, the character of detection tablet, content, having related substance and dissolution, result of the test such as table 12, shown in table 13.Carry
Under conditions of high humidity (90% ± 5%), the stability comparative example to be slightly better than 2,3 of embodiment 1,2,3.
Table 12: 5 days character of high wet test, content, dissolution data
Table 13: 10 days character of high wet test, content, dissolution data
Strong illumination is tested:
Tablet opening is placed in lighting box, places 10 days under conditions of illumination 4500lx ± 500lx, in the 5th day and
Sampling in 10th day, the character of detection tablet, content, there are related substance and dissolution, result of the test such as table 14, shown in table 15.Carry light
Under conditions of (4500lx ± 500lx), the stability comparative example to be slightly better than 2,3 of embodiment 1,2,3.
Table 14: 5 days character of exposure experiments to light, content, dissolution data
Table 15: 10 days character of exposure experiments to light, content, dissolution data
In sum, use when preparing microcapsule Polyethylene Glycol as antitackiness agent, can reach to prevent microcapsule electrostatic from gluing at it
While Lian, moreover it is possible to reach to make the effect of tablet tolerance hot environment unexpectedly.
Experimental example 1
Explore suitable spraying by dissolution rate and prepare the time of microcapsule.Method for preparing tablet thereof such as embodiment 1.Respectively
Measuring 0.1mol/L hydrochloric acid solution 900ml and put in each stripping rotor, the deviation of the actual volume measured and prescribed volume should be ± 1%
Within the scope of, treat dissolution medium temperature constant at 37 DEG C ± 0.5 DEG C, test sample 6 input taking different preparation time respectively is molten
Go out in cup, be respectively sample time 5,10,15,20,30,45 minutes, measure every stripping quantity.Such as table 16, shown in 17, work as spraying
Preparing the microcapsule time controls when 30-35min, and principal agent dissolution time is the shortest.
Table 16: under different spray times, the dissolution (%) of lamivudine in the Compound Tablet of preparation
Table 17: under different spray times, the dissolution of tenofovir disoproxil fumarate in the Compound Tablet of preparation
Experimental example 2
Suitable tableting pressure is explored by dissolution rate.Method for preparing tablet thereof such as embodiment 1.Measure respectively
0.1mol/L hydrochloric acid solution 900ml puts in each stripping rotor, and the deviation of the actual volume measured and prescribed volume should be in ± 1% scope
Within, treat that dissolution medium temperature constant, at 37 DEG C ± 0.5 DEG C, takes test sample 6 input suppressed by different pressures molten respectively
Go out in cup, be respectively sample time 5,10,15,20,30,45 minutes, measure every stripping quantity.Such as table 18, shown in 19, work as tabletting
Pressure controls when 6-7MPa, and the dissolution time of principal agent is the shortest.
Table 18: under different tabletting pressure, the dissolution of lamivudine in the Compound Tablet of preparation
Table 19: under different tabletting pressure, the dissolution of tenofovir disoproxil fumarate in the Compound Tablet of preparation
The above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For Yuan, under the premise without departing from the principles of the invention, it is also possible to make some improvements and modifications, these improvements and modifications also should
It is considered as protection scope of the present invention.
Claims (10)
1. lamivudine-tenofovir Compound Tablet, it is characterised in that: described tablet is by the raw material containing following percetage by weight
Make: lamivudine or its pharmaceutically acceptable salt 10%-20%, tenofovir or its pharmaceutically acceptable salt 10%-20%,
Diluent 10%-40%, binding agent 3%-10%, disintegrating agent 2%-10%, encapsulating material 20%-40%, antitackiness agent is 2%-10%, coating
Powder 1%-5%, fluidizer 0.5%-3%.
Lamivudine the most according to claim 1-tenofovir Compound Tablet, it is characterised in that: described antitackiness agent is poly-second
Glycol.
Lamivudine the most according to claim 1-tenofovir Compound Tablet, it is characterised in that: lamivudine or its pharmacy
The mass ratio of upper acceptable salt and tenofovir or its pharmaceutically acceptable salt is 1:1.
4. according to any one described lamivudine-tenofovir Compound Tablet of claim 1-3, it is characterised in that: diluent
For lactose, microcrystalline Cellulose, mannitol, one or more in dextrin；Binding agent is pregelatinized Starch, polyvidone, hydroxypropyl first
One or more of cellulose；Disintegrating agent is cross-linking sodium carboxymethyl cellulose, polyvinylpolypyrrolidone, the one of carboxymethyl starch sodium or
Several；Encapsulating material is gelatin, arabic gum, hydroxyethyl cellulose, polyvinyl alcohol, polyacrylic acid, acrylic resin, poly-second
One or more of alkene pyrrolidone；Fluidizer is magnesium stearate, silicon dioxide, talcous one or more.
Lamivudine the most according to claim 1-tenofovir Compound Tablet, it is characterised in that described Compound Tablet includes
Lamivudine microcapsule and tenofovir microcapsule.
6. a preparation method for the lamivudine as described in claim 1-5 is arbitrary-tenofovir Compound Tablet, its feature exists
In: described preparation method comprises the steps of: the preparation of (1) lamivudine microcapsule, the preparation of (2) tenofovir microcapsule, (3)
The mixing of adjuvant, the compacting of (4) label, the coating of (5) tablet.
Method the most according to claim 6, it is characterised in that: described preparation method comprises the steps of: (1) rummy husband
Determine the preparation of microcapsule: weigh lamivudine or its pharmaceutically acceptable salt of recipe quantity, encapsulating material, the mass ratio of the two
For 1:2-2:1, first encapsulating material is dissolved in appropriate solvent, forms solution, this solution 5-30% Han encapsulating material, add
The Polyethylene Glycol of recipe quantity, adds lamivudine or its pharmaceutically acceptable salt, under conditions of liquid temperature 5-25 DEG C, and stirring
To being completely dissolved, and then solution spray drying method being prepared microcapsule, preparation temperature 30-120 DEG C, preparation time controls at 30-
35 minutes, stopping when water content≤7% in microcapsule being dried, obtain lamivudine microcapsule, the envelop rate of microcapsule is 95%-99%；
(2) preparation of tenofovir microcapsule: weigh tenofovir or its pharmaceutically acceptable salt of recipe quantity, encapsulating material, two
The mass ratio of person is 1:2-2:1, is first dissolved in appropriate solvent by encapsulating material, forms solution, and this solution contains encapsulating material
5-30%, adds the Polyethylene Glycol of recipe quantity, adds tenofovir or its pharmaceutically acceptable salt, in liquid temperature 5-25 DEG C
Under the conditions of, stirring is to being completely dissolved, and then solution spray drying method is prepared microcapsule, and preparation temperature 30-120 DEG C, during preparation
Between control at 30-35 minute, when water content≤7% in microcapsule stop be dried, obtain tenofovir microcapsule, the envelop rate of microcapsule
For 95%-98%；(3) mixing of adjuvant: by the diluent of recipe quantity, binding agent, disintegrating agent, fluidizer puts in fluid bed and carries out
Sieving after mixing, fully mixing, wherein wind speed is set to 25L/min, mixes 10min；(4) compacting of label: by step (3)
The adjuvant of the fully mixing obtained adds in tablet machine, uses suitable pressure to be pressed into label；(5) coating of tablet: will step
Suddenly the tablet obtained in (4) is placed in seed-coating machine, and appropriate solvent dissolves coating powder, is coated, it is thus achieved that finished product.
Method the most according to claim 7, it is characterised in that: lamivudine in step (1), the mass ratio of encapsulating material
For 1:1；Tenofovir in step (2), the mass ratio of encapsulating material is 1:1.
Method the most according to claim 7, it is characterised in that: in step (4), tablet machine pressure is 6.0-7.0MPa.
Method the most according to claim 7, it is characterised in that: coating weight gain 1%-8% in step (5).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610561406.6A CN106176771B (en) | 2016-07-15 | 2016-07-15 | Lamivudine-tenofovir compound tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610561406.6A CN106176771B (en) | 2016-07-15 | 2016-07-15 | Lamivudine-tenofovir compound tablet and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106176771A true CN106176771A (en) | 2016-12-07 |
| CN106176771B CN106176771B (en) | 2020-02-14 |
Family
ID=57475653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610561406.6A Active CN106176771B (en) | 2016-07-15 | 2016-07-15 | Lamivudine-tenofovir compound tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106176771B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109131198A (en) * | 2018-10-29 | 2019-01-04 | 湖北航天化学技术研究所 | A kind of gas generant for air cell tablet and its preparation process and gasifier system |
| CN110101682A (en) * | 2019-05-17 | 2019-08-09 | 南京望知星医药科技有限公司 | A kind of tenofovir and its preparation process |
| CN110179767A (en) * | 2019-05-17 | 2019-08-30 | 南京望知星医药科技有限公司 | A kind of tenofovir micro-capsule and preparation method thereof |
| CN113288905A (en) * | 2021-07-14 | 2021-08-24 | 石家庄龙泽制药股份有限公司 | Pharmaceutical composition containing dortavir sodium, lamivudine and norfovir disoproxil fumarate |
| CN115517366A (en) * | 2022-11-02 | 2022-12-27 | 宝健（北京）生物技术有限公司 | Spirulina tablet for shortening disintegration time and slowing attenuation of beta-carotene and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101584701A (en) * | 2008-05-20 | 2009-11-25 | 北京星昊医药股份有限公司 | Antiviral composition |
| CN103908456A (en) * | 2012-12-29 | 2014-07-09 | 安徽贝克生物制药有限公司 | Disoproxil fumarate, lamivudine and efavirenz tri-combination compound mini-pill tablet and preparation method thereof |
-
2016
- 2016-07-15 CN CN201610561406.6A patent/CN106176771B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101584701A (en) * | 2008-05-20 | 2009-11-25 | 北京星昊医药股份有限公司 | Antiviral composition |
| CN103908456A (en) * | 2012-12-29 | 2014-07-09 | 安徽贝克生物制药有限公司 | Disoproxil fumarate, lamivudine and efavirenz tri-combination compound mini-pill tablet and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 邢树礼: "喷雾干燥法制备药物微囊和微球的研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109131198A (en) * | 2018-10-29 | 2019-01-04 | 湖北航天化学技术研究所 | A kind of gas generant for air cell tablet and its preparation process and gasifier system |
| CN110101682A (en) * | 2019-05-17 | 2019-08-09 | 南京望知星医药科技有限公司 | A kind of tenofovir and its preparation process |
| CN110179767A (en) * | 2019-05-17 | 2019-08-30 | 南京望知星医药科技有限公司 | A kind of tenofovir micro-capsule and preparation method thereof |
| CN113288905A (en) * | 2021-07-14 | 2021-08-24 | 石家庄龙泽制药股份有限公司 | Pharmaceutical composition containing dortavir sodium, lamivudine and norfovir disoproxil fumarate |
| CN115517366A (en) * | 2022-11-02 | 2022-12-27 | 宝健（北京）生物技术有限公司 | Spirulina tablet for shortening disintegration time and slowing attenuation of beta-carotene and preparation method thereof |
| CN115517366B (en) * | 2022-11-02 | 2024-04-02 | 宝健（北京）生物技术有限公司 | A spirulina tablet for shortening disintegration time and relieving beta-carotene attenuation, and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106176771B (en) | 2020-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106176771A (en) | A kind of lamivudine tenofovir Compound Tablet and preparation method thereof | |
| JP5285105B2 (en) | Pharmaceutical composition | |
| WO2019098259A1 (en) | Pharmaceutical preparation having excellent photostability and drug release properties | |
| CN102791271B (en) | Method for improving dissolvability of anticoagulant | |
| CN106176640B (en) | Pharmaceutical composition containing tofacitinib citrate and preparation method thereof | |
| AU2012357956A1 (en) | Immediate release multi unit pellet system | |
| CN105456270A (en) | Dipeptidyl peptidase IV inhibitor pharmaceutical composition, use and preparation method thereof | |
| CN106860414A (en) | A kind of compound preparation for AntiHIV1 RT activity and preparation method and application | |
| KR20150015500A (en) | Pharmaceutical composition of entecavir and process of manufacturing | |
| CN107334772B (en) | Antiretroviral pharmaceutical composition | |
| JP6204141B2 (en) | Oral rapidly disintegrating composition for solid preparation | |
| CN107913256A (en) | A kind of macitentan oral disnitegration tablet for treating pulmonary hypertension and preparation method thereof | |
| CN104800184B (en) | The smooth sustained release agent pieces of butanedioic acid furan Luo Qu | |
| JP5787762B2 (en) | Coating film, granule and tablet using the same | |
| CN104940160B (en) | Improved Oseltamivir phosphate solid composite and preparation method thereof | |
| EP3437645B1 (en) | Film-coated tablet having high chemical stability of active ingredient | |
| CN106890129A (en) | The extended release dosage form of the general woods of ring benzyl | |
| JP4572296B2 (en) | Pimobendan oral dosage formulation | |
| JP2020518611A (en) | Compositions with improved water solubility and bioavailability | |
| CN104095822A (en) | Daidzein-containing tablet composition and preparation method thereof | |
| CN102552920B (en) | Entecavir-containing medicinal composition and preparation method thereof | |
| WO2020111089A1 (en) | Pharmaceutical composition | |
| CN106389430B (en) | A kind of felodipine Isosorbide Nitrate compound slow-release tablet and preparation method | |
| CN103768034A (en) | Sustained or controlled release solid composition comprising bupropion hydrochloride | |
| CN105326813B (en) | Paroxetine slow release composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Lamivudine-tenofovir compound tablets and preparation method thereof Effective date of registration: 20200403 Granted publication date: 20200214 Pledgee: Hefei high tech Company limited by guarantee Pledgor: Anhui Biochem Bio-Pharmaceutical Co.,Ltd. Registration number: Y2020980001304 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210429 Granted publication date: 20200214 Pledgee: Hefei high tech Company limited by guarantee Pledgor: Anhui Biochem Bio-Pharmaceutical Co.,Ltd. Registration number: Y2020980001304 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Lamivudine tenofovir compound tablet and its preparation method Effective date of registration: 20220621 Granted publication date: 20200214 Pledgee: China Construction Bank Taihe sub branch Pledgor: Anhui Biochem Bio-Pharmaceutical Co.,Ltd. Registration number: Y2022340000013 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |